arrow
E

Emma Nicholson

Royal Marsden Hospital
H指数:20
被引数:1,700

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

纠正:基于体内T细胞清除(ATG与alemtuzumab)的GVHD预防方案比较,用于接受异基因造血干细胞移植的AML患者,移植预处理强度为中等强度方案:代表EBMT急性白血病工作组进行的登记研究

2026-10-230
OAAI
Outcomes for post-transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre UK study

新型疗法时代移植后复发急性淋巴细胞白血病的结局:一项英国多中心回顾性研究

2026-09-180
OAAI
Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

基于体内T细胞清除(ATG与alemtuzumab)的GVHD预防方案比较:在异基因无关供者移植且采用中间强度预处理方案的患者中治疗AML的登记研究——代表EBMT急性白血病工作组

2026-09-100
OAAI
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation

欧洲血液与骨髓移植学会急性白血病工作组关于调节方案对<40岁处于完全缓解期并接受HCT治疗的AML患者结局的影响(移植调节强度评分为3.5-4.0)的研究

2026-07-170
PRE
Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP

异基因SCT后HTLV-1成人T细胞白血病/淋巴瘤(ATLL)患者的结局:EBMT LWP的结果

2026-01-030
PRE
Fludarabine-treosulfan compared with fludarabine-melphalan conditioning for adult acute lymphoblastic leukemia.

氟达拉滨-曲奥硫嘌呤与氟达拉滨-美法仑预处理方案在成人急性淋巴细胞白血病中的比较。

2026-01-010
OAAI
EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY

早期反应和遗传学定义儿童B-ALL一线治疗布利塔尼单抗后的复发风险:一项队列研究

2026-01-010
OA
Evaluating the real-world value of daratumumab addition to multiple myeloma induction therapy by real-world minimal residual disease assessment and extended genetic profiling

通过真实世界微小残留病灶评估和扩展性遗传谱分析,评估将daratumumab加入多发性骨髓瘤诱导治疗中的实际应用价值。

2025-11-100
OAAI
Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT

不同初始干细胞移植策略治疗多发性骨髓瘤的结局:EBMT慢性恶性疾病工作组从统计学角度进行的分析

2025-07-300
OAAI
CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party

CAR-T细胞生产失败和不符合规格的产品在真实世界环境中的情况:EBMT细胞治疗和免疫生物学工作组的一项调查

2025-05-150
PRE
A comparison of Cryopreserved and non-Cryopreserved Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma: A study from the Chronic Malignancies Working Party of the EBMT

比较冷冻保存与非冷冻保存的外周血造血干细胞在多发性骨髓瘤自体移植中的应用:EBMT慢性恶性疾病工作组的研究

2025-03-070
PRE
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

CAR T细胞制备失败的风险因素及大B细胞淋巴瘤患者结局:英国国家CAR T小组报告

2025-03-042
OA
A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

英国对Brexucabtagene Autoleucel治疗复发或难治性成人急性淋巴细胞白血病1年治疗后的意向性治疗分析

BLOOD
IF23.1
2024-11-050
PRE
Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2024-08-310
OAAI
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
LEUKEMIA
IF13.4
2024-07-230
OAAI
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme
2024-04-150
OAAI